Pharmaceuticals

BioRay's ROR1-Targeting Dual-Epitope ADC Drug BR111 Receives Formal Clinical Trial Approval from NMPA

SHANGHAI, Feb. 10, 2025 /PRNewswire/ -- On December 19, 2024, BioRay Pharmaceutical Co., Ltd. ("BioRay") announced that the National Medical Products Administration (NMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 f...

2025-02-10 15:32 2236

Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints

* CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase2b study (CBL-0205) before Phase 3. * 54.2% of participants in the CBL-514 group achieved at least 20% fat volume reduction four week...

2025-02-10 14:15 2260

CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline

SUZHOU, China, Feb. 9, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its key product, Cejemly® (sugemalimab), has been included in the Europe...

2025-02-10 12:20 2404

Keymed Biosciences Announces Approval of Stapokibart For the Treatment of Seasonal Allergic Rhinitis

CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the supplemental New Drug Application (the "sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Ka...

2025-02-08 09:14 5106

Nuance Pharma Announces Approval of Ohtuvayre™ (ensifentrine) in Macau SAR, China

Ohtuvayre™is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients First inhaled COPD treatment providing bronchodilation and non-steroidal anti-inflammatory effects SHANGHAI, Feb. 7, 2025 /PRNewswire/ -- Today, Nuance Pharma ("Nuance") announ...

2025-02-07 09:00 5925

Stroke Detection Innovator Wellumio Enrolls First Patient in Australian Clinical Trial for 'Axana' 0.1T portable magnetic resonance imaging device (Portable MRI study)

"Revolutionary portable device leverages advanced magnetic resonance technology to rapidly detect acute stroke biomarkers, enabling frontline care teams to make faster, life-saving decisions within the critical 'golden hour." A Melbourne hospital images the first patient in Australia using the We...

2025-02-06 21:15 3023

Henlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.

SHANGHAI, Feb. 6, 2025 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along wit...

2025-02-06 19:40 3707

Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer

SUZHOU, China, Feb. 6, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (...

2025-02-06 14:05 3668

Argent BioPharma: A Hidden Gem traded Under $12M--Edison Group Report Assigned a $327M Valuation to Its Breakthrough Epilepsy Treatment

PERTH, Australia, Feb. 6, 2025 /PRNewswire/ -- Argent BioPharma (ASX: RGT) (OTCQB: RGTLF), a clinical-stage biopharmaceutical company brings hope to epilepsy patients. For thousands of patients with refractory epilepsy—commonly referred to as drug-resistant epilepsy—the search for effective trea...

2025-02-06 05:00 2556

Actinogen announces new and unique nonproprietary name of 'emestedastat' for Xanamem

Late-stage Alzheimer's trial opens 10 new sites in USA, with results due in 2025 and 2026 SYDNEY, Feb. 5, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) announces that the World Health Organization (WHO) has granted the nonproprietary name of 'emestedastat' to Actinogen for its Xaname...

2025-02-05 22:18 2913

Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

* Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC * Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC * Serplulimab has now been approved in China, Europe, and sev...

2025-02-05 22:05 3704

I Peace establishes and offers low immunoreaction risk GMP iPS Cells

Three lines of GMP iPS Cells derived from type O female blood are now offered  as off-the-shelf product PALO ALTO, Calif., Feb. 5, 2025 /PRNewswire/ -- Leading GMP cell CDMO I Peace, Inc. (https://ipeace.com/en/ ), specializing in induced pluripotent stem cells (iPSCs) and...

2025-02-05 22:00 2515

From 0 to 100 Trillion: The Rise of Sanyou Bio's Intelligent Molecule Library

SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- In the field of biopharmaceuticals, every technological innovation has the potential to revolutionize treatment strategies. Sanyou Bio's Intelligent Hundred-Trillion Molecule Library (AI-STAL) has emerged from scratch as a shining star, forged through a deca...

2025-02-05 18:00 2147

China Medical University and Healthcare System Pioneers AI-Driven Drug Discovery and Allogeneic CAR-T Therapy: A Groundbreaking Leap in Cancer Treatment

TAICHUNG, Feb. 5, 2025 /PRNewswire/ -- Healthcare Expo Taiwan is a professional-oriented exposition involving healthcare, information/communication, technology, biopharmaceutical and medical device industries. Attended by healthcare professionals from all over the world, the Expo showcases the l...

2025-02-05 13:00 2558

Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immunol...

2025-02-05 12:28 2568

Sequins™ Announces Availability of First Products - Bolsters Team for Commercialization

SAN FRANCISCO, Feb. 4, 2025 /PRNewswire/ -- Sequins, a newly-funded start-up in the next generation sequencing (NGS) ecosystem, announced today the availability of their first commercial products – the Sequins Metagenomics Core Control and Whole Genome Sequencing Core Control Sets, along with an ...

2025-02-05 00:00 2092

GC Labs strengthens global ties and explores new opportunities at Medlab Middle East 2025

YONGIN, South Korea, Feb. 4, 2025 /PRNewswire/ -- GC Labs, a leading clinical laboratory inSouth Korea, announced the successful completion of the second day of the Medlab Middle East 2025, which is being held at theDubai World Trade Centre (DWTC), UAE betweenFebruary 3-6.

2025-02-04 14:56 2569

LabConnect Announces Formation of Strategic Advisory Board and Appointment of Inaugural Members

JOHNSON CITY, Tenn., Feb. 4, 2025 /PRNewswire/ -- LabConnect, a leading provider of central lab services and functional service provider solutions, is proud to announce the formation of its Strategic Advisory Board and the appointment of its inaugural members. This board will further cement LabC...

2025-02-04 02:02 3018

China Jo-Jo Drugstores Announces Strategic Business Restructuring to Strengthen Wholesale Business for Greater Profitability and Growth

HANGZHOU, China, Feb. 3, 2025 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced it has...

2025-02-03 21:00 4213

Nona Biosciences Announces Strategic Collaboration with Invetx for Next-Generation Animal Health Biotherapeutics Discovery

CAMBRIDGE, Mass., Feb. 3, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions from "Idea to IND" (I to I TM), announced today that it has entered into a strategic collaboration with Invetx, Inc. ("Invetx"), aBoston-based animal biotechnology company...

2025-02-03 20:00 2394
1 ... 61626364656667 ... 339

Week's Top Stories